Title : Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.

Pub. Date : 2020 May 31

PMID : 32476052






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS: Here, we demonstrated that this Cycle could be enhanced by the synergistic knock down of PD-L1 through co-delivery of siRNA-PD-L1 (siPD-L1) and imatinib (IMT) in a liposomal nanoparticle. Imatinib Mesylate CD274 molecule Sus scrofa